Swiss drug major Roche Holding AG (RHHBY) said Tuesday that the U.S. Food and Drug Administration has accepted the company's New Drug Applications or NDAs and granted Priority Review for the company's personalised medicine entrectinib.
from RTT - Biotech http://bit.ly/2NhG3TO
via IFTTT
No comments:
Post a Comment